A nose-to-brain nanoparticle aimed at mitochondria eased Parkinson's damage — in mice and neuronal cells

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Two hard problems meet in this paper: Parkinson's is partly a mitochondrial disease of specific neurons, and the brain is deliberately hard to deliver drugs into. A nasal particle engineered to find mitochondria inside neurons is a serious attempt at both — and, today, a mouse result whose long road to a clinic this page will not shorten.

How is the nanoparticle designed to reach mitochondria?

The system, called TCS-RASNPs, combines three choices. The cargo is rosmarinic acid, a plant polyphenol with antioxidant activity. The carrier is a selenium nanoparticle, about 140 nanometers across with a stable positive surface charge. The steering is a coating of chitosan conjugated to triphenylphosphonium (TPP) — a chemical group that accumulates in mitochondria because of the organelle's membrane potential, a targeting trick used across mitochondrial drug delivery. The route is intranasal: nose-to-brain delivery aims to bypass the blood-brain barrier that blocks most systemically given drugs.

What did it do in cells and in mice?

In neuronal cells exposed to MPP+, a toxin that attacks mitochondria and models Parkinson's injury, the particles significantly enhanced survival, reduced apoptosis, lowered intracellular and mitochondrial reactive oxygen species, and improved mitochondrial membrane potential. Pharmacokinetic work showed prolonged retention and significantly higher brain rosmarinic acid levels after intranasal dosing. In mice given MPTP to induce a Parkinsonian state, treatment increased tyrosine hydroxylase expression — a marker of surviving dopamine machinery — reduced alpha-synuclein expression, and normalized oxidative-stress biomarkers in both the substantia nigra pars compacta and the striatum.

What stands between this and patients?

The usual distance, plus delivery-specific questions. MPTP and MPP+ are toxin models that mimic parts of Parkinson's biology, not the decades-long human disease. Nanoparticle platforms must still clear long-term safety, manufacturing consistency, dosing and targeting-accuracy questions in larger animals before any human trial, and TPP-based mitochondrial targeting concentrates a compound in every mitochondria it reaches, not only in the neurons a clinician wants. None of that diminishes the engineering; it prices it. The correct label is a well-built preclinical delivery result in a disease that urgently needs one.

Where the evidence stands

• Established: Parkinson's disease involves loss of dopaminergic neurons in the substantia nigra with mitochondrial dysfunction and oxidative stress central to the pathology; the blood-brain barrier blocks most drugs; and TPP conjugation is an established strategy for concentrating compounds in mitochondria.
• Preliminary: In neuronal cells and MPTP-model mice (ACS Applied Materials & Interfaces, Oct 29, 2026; DOI 10.1021/acsami.6c16278), intranasal mitochondria-targeted rosmarinic acid selenium nanoparticles improved cell survival and mitochondrial membrane potential, raised brain rosmarinic acid levels, increased tyrosine hydroxylase, reduced alpha-synuclein and normalized oxidative-stress markers.
• Absent: Human safety or efficacy of any kind, large-animal data, and any clinical trial of this platform.